Armata Pharmaceuticals
ARMP
26 hedge funds and large institutions have $886K invested in Armata Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
24% more funds holding
Funds holding: 21 → 26 (+5)
40% less capital invested
Capital invested by funds: $1.48M → $886K (-$594K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$132K |
| 2 |
Renaissance Technologies
New York
|
+$43.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$37.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$32.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$907K |
| 2 |
VF
Virtu Financial
New York
|
-$45K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$42.4K |
| 4 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
-$3K |
ARMP Hedge Fund Activity: Q2 2018 in Review
26 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q2 2018, worth a combined $886K — down 40% from $1.48M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ARMP positions and 2 closed out — a net gain of 5 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $132K. The largest seller was Sabby Management, exiting entirely with an estimated $907K sold.
- 26 institutional investors held Armata Pharmaceuticals (ARMP) as of Q2 2018, up from 21 in Q1 2018.
- Funds reported $886K of Armata Pharmaceuticals stock for Q2 2018, down 40% quarter-over-quarter.
- 7 funds opened new Armata Pharmaceuticals positions in Q2 2018 and 2 closed out, a net change of +5 holders.
- The largest Armata Pharmaceuticals buyer in Q2 2018 was Vanguard Group, an estimated $132K added.
- The largest Armata Pharmaceuticals seller in Q2 2018 was Sabby Management, an estimated $907K sold.
Based on aggregated 13F filings for Q2 2018.